| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $5,865,242 | 2 | 4 |
Sells | $18,285,798 | 52 | 96 |
| GOYAL ARJUN | director | 2 | $5.87M | 0 | $0 | $5.87M |
| CHAO DAVID M | Chief Administrative Officer | 0 | $0 | 1 | $120,206 | $-120,206 |
| Anderson Karen M. | Chief People Officer | 0 | $0 | 4 | $882,104 | $-882,104 |
| Weinhoff Gregory M | Chief Business Officer | 0 | $0 | 8 | $1.28M | $-1.28M |
| Accardi Mario Alberto | President, Orexin Program | 0 | $0 | 7 | $1.44M | $-1.44M |
| HUSSAIN IQBAL J | General Counsel | 0 | $0 | 15 | $3.28M | $-3.28M |
| Bush Tia L | Chief Technology & Quality Ofc | 0 | $0 | 8 | $4.71M | $-4.71M |
| SAHA SAURABH | Chief Executive Officer | 0 | $0 | 9 | $6.57M | $-6.57M |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Over the last 12 months, insiders at Centessa Pharmaceuticals plc have bought $5.87M and sold $18.29M worth of Centessa Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Centessa Pharmaceuticals plc have bought $52.04M and sold $7.77M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GOYAL ARJUN (director) — $5.87M.
The last purchase of 417,646 shares for transaction amount of $5.32M was made by GOYAL ARJUN (director) on 2025‑05‑16.
| 2025-12-09 | Sale | Accardi Mario Alberto | President, Orexin Program | 10,000 0.0075% | $28.83 | $288,289 | -5.38% | |
| 2025-12-08 | Sale | Accardi Mario Alberto | President, Orexin Program | 10,000 0.0076% | $30.00 | $300,000 | -5.49% | |
| 2025-11-17 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 40,000 0.0305% | $28.00 | $1.12M | +3.80% | |
| 2025-11-17 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0045% | $27.64 | $165,835 | +3.80% | |
| 2025-11-12 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 40,000 0.035% | $26.00 | $1.04M | +12.66% | |
| 2025-10-27 | Sale | Accardi Mario Alberto | President, Orexin Program | 8,000 0.0062% | $25.00 | $200,000 | +13.72% | |
| 2025-10-15 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0044% | $22.41 | $134,439 | +15.97% | |
| 2025-09-24 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 35,000 0.0262% | $24.00 | $840,000 | +1.17% | |
| 2025-09-16 | Sale | Accardi Mario Alberto | President, Orexin Program | 8,172 0.0061% | $21.40 | $174,846 | +12.42% | |
| 2025-09-15 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0044% | $21.85 | $131,101 | +8.88% | |
| 2025-09-10 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 25,000 0.0181% | $22.00 | $550,000 | +5.42% | |
| 2025-09-10 | Sale | HUSSAIN IQBAL J | General Counsel | 20,000 0.0145% | $22.00 | $440,000 | +5.42% | |
| 2025-09-09 | Sale | Accardi Mario Alberto | President, Orexin Program | 7,000 0.005% | $20.00 | $140,000 | +14.34% | |
| 2025-09-09 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 24,792 0.0178% | $20.00 | $495,840 | +14.34% | |
| 2025-09-09 | Sale | HUSSAIN IQBAL J | General Counsel | 20,000 0.0143% | $20.01 | $400,102 | +14.34% | |
| 2025-08-15 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0043% | $17.23 | $103,380 | +27.62% | |
| 2025-07-29 | Sale | Accardi Mario Alberto | President, Orexin Program | 8,322 0.0062% | $15.23 | $126,751 | +50.10% | |
| 2025-07-25 | Sale | Weinhoff Gregory M | Chief Business Officer | 10,000 0.0076% | $15.56 | $155,598 | +47.89% | |
| 2025-07-21 | Sale | SAHA SAURABH | Chief Executive Officer | 55,000 0.0408% | $15.92 | $875,600 | +41.59% | |
| 2025-07-15 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0044% | $14.93 | $89,567 | +50.33% |
| GOYAL ARJUN | director | 462585 0.3441% | $12.11M | 3 | 0 | <0.0001% |
| CHAO DAVID M | Chief Administrative Officer | 225007 0.1674% | $5.89M | 1 | 3 | <0.0001% |
| SAHA SAURABH | Chief Executive Officer | 221017 0.1644% | $5.78M | 3 | 24 | <0.0001% |
| Accardi Mario Alberto | President, Orexin Program | 178801 0.133% | $4.68M | 0 | 7 | |
| Weinhoff Gregory M | Chief Business Officer | 122279 0.091% | $3.2M | 1 | 17 | <0.0001% |
| Bush Tia L | Chief Technology & Quality Ofc | 121503 0.0904% | $3.18M | 2 | 11 | <0.0001% |
| HUSSAIN IQBAL J | General Counsel | 105386 0.0784% | $2.76M | 1 | 17 | <0.0001% |
| Anderson Karen M. | Chief People Officer | 54322 0.0404% | $1.42M | 0 | 6 | |
| GAP (Bermuda) LTD | 10 percent owner | 9681818 7.2026% | $253.37M | 1 | 0 | <0.0001% |
| De Rubertis Francesco | director | 3936970 2.9288% | $103.03M | 6 | 0 | <0.0001% |
| Medicxi Ventures Management (Jersey) Ltd | 10 percent owner | 3936970 2.9288% | $103.03M | 6 | 0 | <0.0001% |
| GRAINGER DAVID J | Chief Innovation Officer | 908575 0.6759% | $23.78M | 1 | 2 | <0.0001% |
| YVER ANTOINE | EVP & Chairman of Development | 783066 0.5825% | $20.49M | 0 | 17 | |
| Shahidi Javad | Chief Medical Officer | 158932 0.1182% | $4.16M | 0 | 2 | |
| Templeman Thomas | Chief Technology Officer | 135792 0.101% | $3.55M | 1 | 2 | <0.0001% |
| Rotman Harris | SVP Regulatory Affairs | 62625 0.0466% | $1.64M | 0 | 2 | |
| KANTOFF AARON | director | 60000 0.0446% | $1.57M | 1 | 0 | <0.0001% |
| Thorell Marella | Chief Accounting Officer | 1000 0.0007% | $26,170.00 | 1 | 0 | <0.0001% |
$66,736,176 | 136 | 27.54% | $3.8B | |
$193,151,375 | 134 | 8.18% | $3.36B | |
$11,583,737 | 45 | 49.75% | $3.11B | |
$224,382,625 | 44 | 27.62% | $3.16B | |
$148,770,544 | 34 | 80.63% | $3.14B | |
$140,165,669 | 33 | 85.24% | $4.56B | |
$5,066,938 | 27 | 26.38% | $3.37B | |
$61,703,557 | 26 | 40.25% | $3.96B | |
Centessa Pharmaceuticals plc (CNTA) | $150,253,463 | 26 | -52.83% | $3.52B |
$177,517,505 | 13 | 16.65% | $4.5B | |
$137,027,226 | 13 | 28.32% | $3.54B | |
$1,248,715 | 10 | 5.66% | $3.44B | |
$1,711,150 | 9 | 31.59% | $4.09B | |
$32,575,266 | 8 | 37.03% | $3.42B | |
$4,623,072 | 7 | 11.07% | $3.49B | |
$182,500,000 | 6 | 29.00% | $3.79B | |
$461,215 | 5 | 10.35% | $4B | |
$24,000,085 | 4 | 33.26% | $3.47B | |
$50,990,767 | 2 | 19.79% | $4.21B |
| Increased Positions | 57 | +35.85% | 19M | +15.55% |
| Decreased Positions | 72 | -45.28% | 15M | -11.71% |
| New Positions | 26 | New | 4M | New |
| Sold Out Positions | 17 | Sold Out | 3M | Sold Out |
| Total Postitions | 144 | -9.43% | 129M | +3.83% |
| Medicxi Ventures Management (Jersey) Ltd | $529,223.00 | 13.67% | 19.96M | 0 | 0% | 2025-09-30 |
| Avoro Capital Advisors Llc | $286,522.00 | 7.4% | 10.81M | +6M | +116.16% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $266,028.00 | 6.87% | 10.04M | +2M | +19.42% | 2025-09-30 |
| Index Venture Life Associates Vi Ltd | $264,087.00 | 6.82% | 9.96M | 0 | 0% | 2025-09-30 |
| General Atlantic, L.P. | $256,665.00 | 6.63% | 9.68M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $166,410.00 | 4.3% | 6.28M | +2M | +64.06% | 2025-09-30 |
| Janus Henderson Group Plc | $143,371.00 | 3.7% | 5.41M | -1M | -17.21% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $127,356.00 | 3.29% | 4.8M | -1M | -18.68% | 2025-09-30 |
| Farallon Capital Management Llc | $114,823.00 | 2.97% | 4.33M | -198,000 | -4.37% | 2025-09-30 |
| First Light Asset Management, Llc | $96,385.00 | 2.49% | 3.64M | -657,595 | -15.32% | 2025-09-30 |